Published in Clin Cancer Res on January 01, 2009
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res (2009) 3.61
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell (2013) 2.11
Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase. J Biol Chem (2011) 1.60
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One (2013) 1.29
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate (2012) 1.11
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem (2013) 1.11
Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem (2011) 1.10
Adaptation or selection--mechanisms of castration-resistant prostate cancer. Nat Rev Urol (2012) 1.10
Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. J Med Chem (2011) 1.09
Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. PLoS One (2010) 1.09
Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol (2012) 1.00
Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One (2011) 0.99
HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol Med (2014) 0.98
CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. Oncotarget (2014) 0.95
Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem (2014) 0.93
Telomerase as an important target of androgen signaling blockade for prostate cancer treatment. Mol Cancer Ther (2010) 0.93
Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells. PLoS One (2011) 0.92
Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation. Int J Biol Sci (2014) 0.91
Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol (2014) 0.89
Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells. J Cell Physiol (2011) 0.88
Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases. Int J Biol Sci (2014) 0.87
A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression. J Biol Chem (2012) 0.86
Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. Int J Mol Sci (2013) 0.86
TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth. PLoS One (2011) 0.85
Transcriptional activity of c-Jun is critical for the suppression of AR function. Mol Cell Endocrinol (2013) 0.84
Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS One (2011) 0.84
Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells. Evid Based Complement Alternat Med (2013) 0.82
Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. PLoS One (2012) 0.82
CaMKK2: a novel target for shaping the androgen-regulated tumor ecosystem. Trends Mol Med (2013) 0.82
Castration-resistant prostate cancer: potential targets and therapies. Biologics (2012) 0.81
Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine (Lond) (2012) 0.81
Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications. Endocr Relat Cancer (2015) 0.81
Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. EBioMedicine (2016) 0.81
Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. Br J Cancer (2009) 0.80
The curcumin analog ca27 down-regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells. Prostate (2011) 0.80
Role of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S phase. PLoS One (2013) 0.79
To die or to survive, a fatal question for the destiny of prostate cancer cells after androgen deprivation therapy. Cancers (Basel) (2011) 0.78
Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Oncotarget (2015) 0.78
20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer. PLoS One (2014) 0.77
The role of androgen receptor expression in the curative treatment of prostate cancer with radiotherapy: a pilot study. Biomed Res Int (2015) 0.76
Arrestin2 modulates androgen receptor activation. Oncogene (2014) 0.76
AR Signaling and the PI3K Pathway in Prostate Cancer. Cancers (Basel) (2017) 0.75
Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation. Mol Cancer Ther (2016) 0.75
Bioengineered viral vectors for targeting and killing prostate cancer cells. Bioeng Bugs (2010) 0.75
The inhibitory effects of AR/miR-190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism. Sci Rep (2015) 0.75
The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth. J Biol Chem (2016) 0.75
A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo. Mol Ther Nucleic Acids (2016) 0.75
A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland. Cancers (Basel) (2017) 0.75
Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo. Int J Mol Sci (2013) 0.75
Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase. Int J Mol Med (2017) 0.75
The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Sci Rep (2017) 0.75
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79
Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A (2007) 4.04
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol (2003) 3.01
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev (2005) 2.87
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol (2007) 2.48
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell (2006) 2.29
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell (2013) 2.11
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95
Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis. Arch Ital Urol Androl (2015) 1.95
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst (2005) 1.90
Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell (2004) 1.82
Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res (2007) 1.82
MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res (2009) 1.82
Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res (2004) 1.81
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76
Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol (2004) 1.76
Fish and chips: various methodologies demonstrate utility of a 16,006-gene salmonid microarray. BMC Genomics (2005) 1.75
Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. J Natl Cancer Inst (2013) 1.70
Children's perspectives on their relationships with their nonresident fathers: influences, outcomes and implications. J Child Psychol Psychiatry (2004) 1.68
Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res (2007) 1.67
Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res (2004) 1.66
Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther (2004) 1.63
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int J Cancer (2012) 1.60
Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res (2006) 1.59
Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate (2010) 1.59
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res (2013) 1.58
Insulin receptor expression by human prostate cancers. Prostate (2009) 1.57
Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res (2005) 1.55
The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem (2007) 1.55
Assessing information and decision preferences of men with prostate cancer and their partners. Cancer Nurs (2002) 1.54
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer (2008) 1.54
TP53INP1 as new therapeutic target in castration-resistant prostate cancer. Prostate (2011) 1.51
Provision of individualized information to men and their partners to facilitate treatment decision making in prostate cancer. Oncol Nurs Forum (2003) 1.50
5-Aza-2'-deoxycytidine increases sialyl Lewis X on MUC1 by stimulating β-galactoside:α2,3-sialyltransferase 6 gene. Int J Biochem Cell Biol (2010) 1.48
Problems with co-funding in Canada. Science (2005) 1.48
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res (2004) 1.44
The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem (2002) 1.44
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate (2004) 1.40
Prostate specific antigen: an updated review. Can J Urol (2003) 1.39
A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int (2007) 1.38
miRDeep*: an integrated application tool for miRNA identification from RNA sequencing data. Nucleic Acids Res (2012) 1.37
The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol (2011) 1.33
Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Oncogene (2003) 1.32
Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women. Sex Transm Dis (2010) 1.29
ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Res (2008) 1.29
Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate (2002) 1.28
Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res (2011) 1.28
Regulation of the versican promoter by the beta-catenin-T-cell factor complex in vascular smooth muscle cells. J Biol Chem (2005) 1.21
Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res (2002) 1.20
Loss of PTEN is associated with progression to androgen independence. Prostate (2006) 1.20
Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer. Hum Mol Genet (2012) 1.19
Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol (2007) 1.19
p54nrb is a transcriptional corepressor of the progesterone receptor that modulates transcription of the labor-associated gene, connexin 43 (Gja1). Mol Endocrinol (2009) 1.18
RanBPM, a nuclear protein that interacts with and regulates transcriptional activity of androgen receptor and glucocorticoid receptor. J Biol Chem (2002) 1.18
GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.18
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int (2008) 1.17
Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res (2012) 1.17
Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res (2010) 1.16